- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06415305
A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
The Efficacy and Safety of Winlevi in Skin of Color Patients With Acne
Acne vulgaris is the most common skin disease in patients with skin of color and second most common in Caucasian population. The global prevalence is thought to be as high as 60-80% in individuals 12-25 years of age. However, it is not limited to only teenagers but also to adults, especially adult females. The pathogenesis of acne is multifactorial. Genetics may also play a role. The treatment pathway should be directed to different pathogenic factors including, excessive sebum production, hyper keratinization, P. acnes, and inflammation.
Data is limited for skin of color patients in Phase III registration trials. Data is limited because there a few studies that focus on patients with skin of color. Therefore, a unique study dedicated to patients with skin of color in a real-world setting will be welcome to add further evidence to phase III data.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Skin Sciences, Pllc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
i. Outpatient, male or female subjects of any race (Fitzpatrick skin types IV, V, VI), and at least 12 years of age or older. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study:
A female is considered of childbearing potential unless she is:
- postmenopausal for at least 12 months prior to study drug administration;
- without a uterus and/or both ovaries; or
- has been surgically sterile for at least 6 months prior to study drug administration.
Reliable methods of contraception are:
- hormonal methods or intrauterine device in use > 90 days prior to study drug administration;
- barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
- vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice)
[Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.] ii. Facial acne IGA score of 3 or 4. iii. Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.
Exclusion Criteria:
i. Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
ii. Allergy or sensitivity to any component of the test medications (Section 5.2).
iii. Subjects who have not complied with the proper wash-out periods for prohibited medications (Supplement I).
iv. Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study.
v. Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris vi. Evidence of recent alcohol or drug abuse. vii. History of poor cooperation, non-compliance with medical treatment, or unreliability.
viii. Exposure to an investigational drug study within 30 days of the Baseline Visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Winlevi (clascoterone) 1% cream
|
Dosed twice daily (BID)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint of this study is the percent of patients who achieve clear or almost clear on IGA at week 16.
Time Frame: Week 16
|
Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of total lesion reduction at week 16 compared to baseline
Time Frame: Week 16
|
Week 16
|
|
Percent of inflammatory lesion reduction at week 16 compared to baseline
Time Frame: Week 16
|
Week 16
|
|
Percent of non-inflammatory lesion reduction at week 16 compared to baseline
Time Frame: Week 16
|
Week 16
|
|
Tolerability measures of erythema based on 5-point severity scale
Time Frame: Week 52
|
The score in the scale ranges from 0-4.
Lower score represents absence of erythema and higher score represents severe condition.
|
Week 52
|
Tolerability measures of dryness based on 5-point severity scale
Time Frame: Week 52
|
The score in the scale ranges from 0-4.
Lower score represents absence of dryness and higher score represents severe condition.
|
Week 52
|
Tolerability measures of peeling based on 5-point severity scale
Time Frame: Week 52
|
The score in the scale ranges from 0-4.
Score 0 represents absence of peeling and Score 4 represents 'Extensive peeling'.
|
Week 52
|
Assessment of skin oiliness based on 5-point severity scale
Time Frame: Week 52
|
The score in the scale ranges from 0-4.
Score 0 represents absence of Oiliness and Score 4 represents severe condition.
|
Week 52
|
Tolerability measures of pruritus based on 6-point severity scale
Time Frame: Week 52
|
The score in the scale ranges from 0-5.
Lower score represents absence of discomfort and higher score represents severe condition.
|
Week 52
|
Tolerability measures of burning/stinging based on 6-point severity scale
Time Frame: Week 52
|
The score in the scale ranges from 0-5.
Lower score represents absence of discomfort and higher score represents severe condition.
|
Week 52
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WINSCO - 2023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Nexgen Dermatologics, Inc.Unknown
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.RecruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.RecruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
Clinical Trials on Winlevi (clascoterone) 1% cream
-
Sun Pharmaceutical Industries LimitedNot yet recruiting
-
Sun Pharmaceutical Industries LimitedCompletedAcne VulgarisUnited States
-
Sun Pharmaceutical Industries LimitedActive, not recruitingAcne VulgarisUnited States
-
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Not yet recruiting
-
Sun Pharmaceutical Industries LimitedActive, not recruiting
-
University of PennsylvaniaNot yet recruitingPilonidal Sinus | Pilonidal Disease | Pilonidal Cyst | Pilonidal Disease of Natal CleftUnited States
-
Stanford UniversityRecruiting
-
Cassiopea SpACompletedAcne VulgarisUnited States, Bulgaria, Georgia, Poland, Romania, Serbia
-
Cassiopea SpACompletedAcne VulgarisUnited States, Georgia, Ukraine
-
Cassiopea SpACompletedAcne VulgarisUnited States, Bulgaria, Romania, Serbia, Georgia, Poland, Ukraine